Empagliflozin 10 mg + Sitagliptin 100 mg is a combination oral antidiabetic medication designed to help manage type 2 diabetes mellitus. Empagliflozin belongs to the SGLT2 inhibitor class, which works by increasing glucose excretion through the urine, thereby reducing blood sugar levels. Sitagliptin is a DPP-4 inhibitor that helps increase insulin release in response to meals and decreases glucagon production, maintaining better post-meal glucose control. This combination provides dual action to improve glycemic control in adults with type 2 diabetes, particularly in patients who are inadequately controlled with diet, exercise, and monotherapy. The medication is convenient with once-daily dosing and may help in weight management due to the SGLT2 mechanism.
